References
- TackJCorsettiMNaloxegol for the treatment of opioid-induced constipationExpert Rev Gastroenterol Hepatol20148885586125220391
- CheyWDWebsterLSostekMLappalainenJBarkerPNTackJNaloxegol for opioid-induced constipation in patients with noncancer painN Engl J Med2014370252387239624896818
- PoulsenJLBrockCOlesenAENilssonMDrewesAMClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionClin Exp Gastroenterol2014734535825278772
- KumarLBarkerCEmmanuelAOpioid-induced constipation: pathophysiology, clinical consequences, and managementGastroenterol Res Pract2014201414173724883055
- BellTAnnunziataKLeslieJBOpioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness SurveyJ Opioid Manag20095313714419662923
- AbramowitzLBeziaudNLabrezeLPrevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS studyJ Med Econ201316121423143324102123
- CoyneKSLoCasaleRJDattoCJSextonCCYeomansKTackJOpioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart reviewClinicoecon Outcomes Res2014626928124904217
- OlesenAEDrewesAMValidated tools for evaluating opioid-induced bowel dysfunctionAdv Ther201128427929421437762
- TarumiYWilsonMPSzafranOSpoonerGRRandomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patientsJ Pain Symptom Manage201345121322889861
- CandyBJonesLGoodmanMLDrakeRTookmanALaxatives or methylnaltrexone for the management of constipation in palliative care patientsCochrane Database Syst Rev20111CD00344821249653
- MeissnerWLeyendeckerPMueller-LissnerSA randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipationEur J Pain200913566418762438
- ThomasJKarverSCooneyGAMethylnaltrexone for opioid-induced constipation in advanced illnessN Engl J Med2008358222332234318509120
- MackeyACGreenLGreenePAviganMMethylnaltrexone and gastrointestinal perforationJ Pain Symptom Manage2010401e1e320619194
- Entereg (alvimopan) [package insert]Lexington, MACubist Pharmaceuticals, Inc2013
- EldonMASongDNeumannTANKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical modelsPoster presented at: 18th Annual Clinical Meeting of the American Academy of Pain ManagementSeptember 2007Las Vegas, NV, USA
- Movantik (naloxegol) [package insert]Wilmington, DEAstraZeneca Pharmaceuticals LP2014
- WebsterLDharSEldonMMasuokaLLappalainenJSostekMA phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipationPain201315491542155023726675
- FlockhartDDrug Interactions: Cytochrome P450 Drug Interaction Table – P450 Drug Interaction Table: Abbreviated “Clinically Relevant” Table2007 [June 30, 2011; cited July 30, 2011] Available from: http://medicine.iupui.edu/clinpharm/DDIs/ClinicalTable.aspx
- BuiKSheFSostekMThe effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegolJ Clin Pharmacol201454121368137424945932
- BuiKSheFSostekMThe effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegolJ Clin Pharmacol201454121375138224946021
- WebsterLCheyWDTackJLappalainenJDivaUSostekMRandomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipationAliment Pharmacol Ther201440777177925112584
- GottfridssonCCarlsonGLappalainenJSostekMEvaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo-and positive-controlled crossover thorough QT/QTc study in healthy volunteersClin Ther201335121876188324238792
- von RoennJHTackJBarkerPNLoweESFleischmannCSostekMChallenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation (OIC)Poster presented at: MASCC/ISOO International Symposium on Supportive Care in CancerJune 2013Berlin, Germany
- http://www.deadiversion.usdoj.gov/fed_regs/rules/2015/fr0123_3.htm[web page on the internet]Washington, DCUS Department of Justice Office of Diversion Control2014 [Filed October 28, 2014]. Available from: http://perma.cc/TD4L-CFKWAccessed January 26, 2015